Arcus Biosciences, Inc.
Moat Score — Arcus Biosciences, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Arcus has built an extensive patent estate of over 850 pending or issued patents, including 41 issued U.S. patents, around a differentiated internal small-molecule and antibody discovery platform spanning both oncology and a newer inflammation pillar. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biopharmaceutical company with no approved products, Arcus has no cost advantage; it owns no manufacturing facilities and relies entirely on third-party, largely single-source suppliers for drug substance and product. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Approved oncology drugs typically carry strong pricing power, and Arcus's lead candidate casdatifan targets a market (renal cell carcinoma) where Merck's belzutifan has already proven commercial viability, but Arcus has no approved product today and recently lost its lead anti-TIGIT asset to a Phase 3 futility failure, so this pricing power remains unproven. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Arcus's drug candidates are discrete therapeutic products, not a platform whose value compounds as more patients or partners use it — there is no network effect in this business model. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | There is no recurring customer relationship or embedded workflow to create switching costs; Arcus's closest analog, deep structural ties to partner Gilead through options and board representation, is a partnership dynamic rather than a customer switching cost. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Arcus is competing directly against enormous, well-funded oncology franchises at AstraZeneca, Merck, Bristol-Myers Squibb, and Roche across nearly every mechanism it is pursuing (HIF-2α, TIGIT, PD-1, CD73), leaving little protection from scale economics in its own right. |